Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Annals of the Rheumatic Diseases

Volumn 78, Issue 11, 2019, Pages 1454-1462

  Fleischmann, Roy M ^a   Genovese, Mark C ^b   Enejosa, Jeffrey V ^c   Mysler, Eduardo ^d   Bessette, Louis ^e,f   Peterfy, Charles ^g   Durez, Patrick ^h   Ostor, Andrew ⁱ   Li, Yihan ^c   Song, In Ho ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c ABBVIE INC   (United States)

^d Organización Médica de Investigación   (Argentina)

^e UNIVERSITÉ LAVAL   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g Spire Sciences Inc   (United States)

^h UCL   (Belgium)

ⁱ CABRINI INSTITUTE   (Australia)

Author keywords

dmards (biologic); dmards (synthetic); methotrexate; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO; UPADACITINIB; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS;

ADULT; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; JOINT EXAMINATION; JOINT FUNCTION; MAJOR CLINICAL STUDY; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SWOLLEN JOINT COUNT; TENDER JOINT COUNT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

EID: 85073303155     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-215764     Document Type: Article

References (22)

1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force. Ann Rheum Dis 2016;75: 3-15.
2. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. The Lancet 2004;364: 263-9.
3. Versteeg GA, Steunebrink LMM, Vonkeman HE, et al. Long-Term disease and patientreported outcomes of a continuous treat-To-Target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol 2018;37: 1189-97.
4. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76: 960-77.
5. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68: 1-26.
6. Burmester GR, Kremer JM, Van Den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2018;391: 2503-12.
7. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. The Lancet 2018;391: 2513-24.
8. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECTMONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. The Lancet 2019;393: 2303-11.
9. van Vollenhoven RTT, Pangan AL, Friedman A, et al. A phase 3, randomized, doubleblind study comparing Upadacitinib monotherapy to MTX monotherapy in MTX-Naive patients with active rheumatoid arthritis. Arthritis and Rheumatology 2018.
10. Fleischmann R, Pangan AL, Song In-Ho, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase 3, Double-Blind, randomized controlled trial. Arthritis Rheumatol 2019.
11. Van Der Heijde D. How to read radiographs according to the Sharp/van Der Heijde method. J Rheumatol 1999;26: 743-5.
12. Van Der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35: 26-34.
13. Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: The rheumatology common toxicity criteria v.2.0. J Rheumatol 2007;34: 1401-14.
14. NCI. Common terminology criteria for adverse events (CTCAE) version 4.0 NIH publication; 2009.
15. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65: 559-70.
16. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): A double-blind, placebo-controlled, randomised trial. The Lancet 2008;371: 987-97.
17. Taylor PC, Keystone EC, Van Der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. NEngl J Med 2017;376: 652-62.
18. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. NEngl J Med 2016;374: 1243-52.
19. Genovese MC, van Vollenhoven RF, Wilkinson B, et al. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther 2016;18.
20. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66: 2675-84.
21. Kim SC, Schneeweiss S, Liu J. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res 2013;65: 1600-7.
22. Chung W-S, Peng C-L, Lin C-L, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: A nationwide cohort study. Ann Rheum Dis 2014;73: 1774-80.